Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Ashley Boam on FDA’s Proposed Quality Maturity Model

No items found.

Redica Announces Addition of Jason Kerr

No items found.
Conference Spotlight

Latest Chinese Pharmacopoeia Includes Updated Chapters in Key Areas

No items found.
Conference Spotlight

FDA’s Vision for the Future of Biomanufacturing

No items found.
Conference Spotlight

89 Products Filed as NDAs Now BLAs Under Regulation Change

No items found.

Redica Systems Welcomes Chelsey Langan

No items found.
Conference Spotlight

Overcoming the Quality Challenges of a CAR-T Cell Product: One Company’s Experience

No items found.
Conference Spotlight

Impact of Brexit on UK & Northern Ireland Medical Device Regulations

No items found.
Enforcement

FDA Warning Letters: 11/22/2020 & 12/1/2020

No items found.
Conference Spotlight

FDA Cracks Down on Unapproved HCT Products

No items found.

On-Demand Webinar | The Ecosystem for Smart Combination Products

No items found.
Conference Spotlight

Russian Drug Regulator, MHRA, and FDA Processes for Evaluating & Escalating Drug GMP Inspection Findings

No items found.

How to Identify Data Integrity (and Other) Trends

No items found.
Conference Spotlight

CBER Director Wilson Bryan On How To Cut CGT Product Approval Times In Half

No items found.
Press Release

Govzilla Announces New Platform, Name Change to Redica Systems

No items found.
Enforcement

FDA Warning Letters Week Of 11/8/2020: Process Validation Failures

No items found.

FDA Takes Quality Systems Approach to CGT Inspections

No items found.

Top 10 Pharma Inspection Findings from FDA, MHRA, and the Russian Drug Regulator

No items found.